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Epistasis and Its Implications for Personal Genetics
Jason H. Moore1,2,3,4,5,* and Scott M. Williams6The widespread availability of high-throughput genotyping
technology has opened the door to the era of personal genetics,
which brings to consumers the promise of using genetic variations
to predict individual susceptibility to common diseases. Despite
easy access to commercial personal genetics services, our knowl-
edge of the genetic architecture of common diseases is still very
limited and has not yet fulﬁlled the promise of accurately predict-
ing most people at risk. This is partly because of the complexity
of the mapping relationship between genotype and phenotype
that is a consequence of epistasis (gene-gene interaction) and
other phenomena such as gene-environment interaction and
locus heterogeneity. Unfortunately, these aspects of genetic archi-
tecture have not been addressed in most of the genetic association
studies that provide the knowledge base for interpreting large-
scale genetic association results. We provide here an introductory
review of how epistasis can affect human health and disease and
how it can be detected in population-based studies. We provide
some thoughts on the implications of epistasis for personal
genetics and some recommendations for improving personal
genetics in light of this complexity.
Introduction
The discovery and characterization of BRCA1 (MIM
113705) and BRCA2 (MIM 600185) and their speciﬁc
mutations as signiﬁcant risk factors for familial breast
cancer (MIM 114480) ushered in the era of commercial
genetic testing.1 There is no question that our ability to
test for the presence of mutations in these two genes plays
some role in understanding and preventing this form of
cancer. However, much of familial breast cancer remains
unexplained by BRCA1 and BRCA2, and the elusive
BRCA3 has yet to be identiﬁed.2 It is entirely possible
that the remaining genetic risk factors for familial breast
cancer are a combination of rare variants with interme-
diate penetrance and common variants, such as SNPs, that
have low penetrance. However, the common disease-
common variant (CDCV) model has thus far failed to
uncover new variants that explain a large fraction of the
genetic risk. The data, as reviewed by Ripperger et al., indi-
cate that there is currently no evidence that genetic testing
for variants of low penetrance is useful for predicting risk.2
Therefore, before meaningful new genetic testing services
can be offered, we must substantially improve our under-
standing of the genetic architecture of familial breast
cancer, where genetic architecture is deﬁned as (1) the setThe Americanof genes and DNA sequence involved in the disease, (2)
their variation in the population, and (3) their speciﬁc
effects on the phenotype.3 We argue here, based on the
emerging data and analyses, that elucidating the genetic
architecture of breast cancer and comparable diseases
must focus on underlying complexity.
The current strategy for revealing genetic architecture is
to carry out a genome-wide association study (GWAS) with
amillion or more SNPs or other variants that capture much
of the common variation in the human genome by tagging
blocks of variants that are in linkage disequilibrium.4,5 This
approach is based on the hypothesis that scanning the
entire genome for single SNP associations in an unbiased
or agnostic manner that ignores what we know about
disease pathobiology will reveal much of the unexplained
genetic architecture of a particular disease. The prevalent
analytical strategy of searching for strong single SNP effects
without regard to the rest of the genome or exposure was
initially developed for diseases with few known etiologic
factors. This approach has been applied universally to all
GWAS analyses, producing deceptive results because of
confounding, as occurs with smoking and lung cancer.6
Despite the promise of this technology and the time and
ﬁnancial resources already expended, the results have
been generally underwhelming in terms of elucidating
the genetic architecture of common complex disease and
explaining a majority of the genetic risks. Consider, for
example, the application of GWAS for identifying cancer-
susceptibility genes. A recent review of these studies shows
that a number of new susceptibility loci have been identi-
ﬁed for several types of cancer, including breast, prostate,
colorectal, lung, and skin.7 The identiﬁcation of new asso-
ciations is certainly important. However, as Easton and
Eeles note, the increase in risk for the susceptibility alleles
at each of these loci is generally 1.3-fold or less.7 For
familial breast cancer, Easton et al. reported ﬁve signiﬁcant
replicated associations that were identiﬁed by GWAS in
a three-stage study design.8 Four of these variants were in
known genes, and one was located in a hypothetical
gene. Assuming a multiplicative model, these ﬁve loci
combine to explain only 3.6% of the excess familial risk
of breast cancer and, as suggested by Ripperger et al.,2
were not deemed to be suitable for genetic testing as a result
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two additional stages of testing and replication, two addi-
tional susceptibility loci were identiﬁed with odds ratios
of 1.11 and 0.95, respectively, each accounting for much
less than 1% of the familial risk of breast cancer.9 When
combined with the previous known genetic risk factors
for familial breast cancer, the estimated fraction of risk
explained is approximately 5.9%. This is in stark contrast
to BRCA1 and BRCA2 mutations, which account for
between 20% and 40% of familial breast cancer. Although
the application of GWAS to familial breast cancer has
generated new knowledge, it has not resulted in new
genetic tests that can be used to predict and prevent
familial breast cancer. These results are discouraging for
more common diseases such as sporadic breast cancer
and type 2 diabetes that are likely to have a much more
complex genetic architecture. As Clark et al. predicted,
our success with GWAS depends critically on the assump-
tions we make about disease complexity.10
The limits of GWAS, as revealed through the study of
familial breast cancer, do not represent isolated examples.
In fact, very few SNPs with odds ratios above 1.5 have
been discovered and replicated for any common human
disease, suggesting that their use in genetic testing will be
limited. This limitation was pointed out in a recent study
by Jakobsdottir et al. showing that SNPs identiﬁed by
GWAS for a variety of diseases make poor classiﬁers of
disease, thus calling into question their usefulness for risk
assessment by genetic testing.11 The same conclusions
have beenpresented byKraft et al.12 Despite these cautions,
commercial genotyping is currently being offered directly
to the consumer at affordable prices, and, although there
are appropriate disclaimers, it is obvious that the avail-
ability of cheap genetic testing is fostering the perception
that the era of personal genetics is upon us. However, it is
important to note that the ability to inexpensivelymeasure
one million or more SNPs in an individual’s genome does
not, in the absence of accurate genotype-phenotype
maps, provide clinically relevant information in most
situations. Nonetheless, several commercial direct-to-con-
sumer genetic testing services are now available for less
than $1000, and in some cases less than $500.13
Barring future regulation, it appears as though personal
genetics is here to stay. Given this reality, it is important
to assess the impact that genetic architecture will have
on the utility of the results being provided to the
consumer. It is our working hypothesis that epistasis, or
gene-gene interaction, plays an important role in the
genetic architecture of common diseases and thus must
be characterized if personal genetics is to have an impact
on the health of the consumer. We provide here an intro-
duction to epistasis and a theory for why it is ubiquitous
in human biology. We then provide an overview of the
analytical tools that are necessary to detect and charac-
terize epistasis in genetic association studies. Finally, we
provide a discussion of the implications of epistasis for
personal genetics and then provide some recommenda-
tions for how to move forward under the assumption310 The American Journal of Human Genetics 85, 309–320, Septemthat the genetic architecture of common disease is ex-
tremely complex.
What Is Epistasis?
William Bateson, who ﬁrst coined the term ‘‘genetics’’ (see
historical account by Patrick Bateson14), also coined the
word ‘‘epistasis’’ in the early 1900s to explain deviations
from Mendelian inheritance.15 The term ‘‘epistasis’’ liter-
ally means ‘‘standing upon,’’ and Bateson used it to
describe characters that were layered on top of other char-
acters, thereby masking their expression. The epistatic
characters had to be removed before the underlying hypo-
static characters could be revealed. The commonly used
deﬁnition of epistasis, an allele at one locus masking
the expression of an allele at another locus, reﬂects this
original deﬁnition. As reviewed recently by Tyler et al.,
eye color determination in Drosophila provides a classic
example.16 The genes scarlet, brown, and white play major
roles in a simpliﬁed model of Drosophila eye pigmentation.
Eye pigmentation in Drosophila requires the synthesis and
deposition of both drosopterins, red pigments synthesized
from GTP, and ommochromes, brown pigments synthe-
sized from tryptophan. A mutation in brown prevents
production of the bright red pigment, resulting in a ﬂy
with brown eyes, and a mutation in scarlet prevents
production of the brown pigment, resulting in a ﬂy with
bright red eyes. In a ﬂy with a mutation in the white
gene, neither pigment can be produced, and the ﬂy will
have white eyes regardless of the genotype at the brown
or scarlet loci. In this example, the white gene is epistatic
to brown and scarlet: a mutant genotype at the white locus
masks the genotypes at the other loci.
Since Bateson, there have beenmanydifferent and evolv-
ing deﬁnitions of epistasis or gene-gene interaction.16–29
For example, Fisher deﬁned epistasis in a statistical manner
as an explanation for deviation from additivity in a linear
model.30 This nonadditivity of genetic effects measured
mathematically is different from Bateson’s more biological
deﬁnitionof epistasis.Wehavepreviouslymade thedistinc-
tion between Bateson’s biological epistasis and Fisher’s
statistical epistasis.29 This distinction is important to keep
in mind when thinking about the genetic architecture of
common human diseases because biological epistasis
happens at the cellular level in an individual whereas statis-
tical epistasis is a pattern of genotype-to-phenotype rela-
tionships that results from genetic variation in a human
population. This distinction becomes important when
attempting todrawabiological conclusion froma statistical
model that describes a genetic association. Moore and
Williams29 and Phillips22 have discussed the idea that
moremoderndeﬁnitions of epistasismaybeneeded in light
of our new knowledge about gene networks and biological
systems. However, the classic deﬁnitions provided by
Bateson and Fisher still provide a good starting point for
thinking about gene-gene interactions.15,30
To illustrate the concept of statistical interaction,
consider the following simple example of epistasis in theber 11, 2009
Figure 1. A Simple Biochemical Systems
Model that Is Consistent with a Complex
Genetic Model
(A) Penetrance function showing an
exclusive OR (XOR) pattern of high-risk
(shaded) and low-risk (unshaded) geno-
type combinations for two biallelic SNPs.
(B) A Petri net model of a biochemical
system under the control of the two SNPs
from the genetic model in (A). SNPA
controls the diameter of the ‘‘arc’’ or
‘‘pipe’’ carrying molecules of type 1, which
are converted to molecules of type 2 at
a constant rate governed by the ﬁrst
‘‘transition’’ (lightning) on the left (wider
pipes ¼ larger diameter). SNPA is pleio-
tropic and also controls the rate at which
molecules of type 2 are converted to molecules of type 3 (wider lightning bolts¼ faster rate). SNPB controls the arc or pipe carrying mole-
cules of type 2 to the second transition, which converts them to molecules of type 3. When executed as part of a threshold model, the
output of this system matches the distribution of high-risk and low-risk genotypes. This Petri net model demonstrates that a simple
biochemical systems model can underlie a nonlinear genetic model.form of a penetrance function. Penetrance is simply the
probability (P) of disease (D) given a particular combina-
tion of genotypes (G) that was inherited (i.e., P[DjG]). Let
us assume for two SNPs labeled A and B that genotypes
AA, aa, BB, and bb have population frequencies of 0.25
whereas genotypes Aa and Bb have frequencies of 0.5.
Let us also assume that individuals have a very high risk
of disease if they inherit Aa or Bb but not both (i.e., the
exclusive OR [XOR] logic function). What makes this
model interesting is that disease risk is entirely dependent
on the particular combination of genotypes inherited at
more than one locus. The penetrances for each individual
genotype in this model are all the same and are computed
by summing the products of the genotype frequencies
and penetrance values. Heritability can be calculated as
outlined by Culverhouse et al.31 Thus, in this model, there
is no difference in disease risk for each single-locus geno-
type as speciﬁed by penetrance values. This model is
labeled M170 by Li and Reich in their categorization of
genetic models involving two SNPs and is an example of
a pattern that is not separable by a simple linear func-
tion.32 This model is a special case in which all of the
heritability results from epistasis or nonlinear gene-gene
interaction.
Although highly illustrative, the XOR model and others
like it are often criticized for lack of biological plausibility.
For example, the XOR model does not ﬁt with Mendelian
concepts of epistasis that are based on interactions
between SNPs with recessive and dominant effects. There
are two important points to keep inmind when embracing
a complex view of genetic architecture: ﬁrst, we do not yet
know what a plausible epistasis model is, because we have
yet to systematically evaluate nonlinear genetic models of
human disease, and second, we have not yet begun to vali-
date these models in experimental systems. Therefore, our
knowledge of the diversity of genetic models underlying
common diseases is in its infancy. However, we can begin
to think about biological plausibility via computational
thought experiments.33 To this end, Moore and HahnThe Americandeveloped a computational system for discovering systems
biology models that are consistent with epistasis models
such as XOR.34 Here, Petri nets were used as a discrete
dynamic system modeling tool (see Moore and Hahn for
details34). Figure 1A shows a variation on an XOR-based
penetrance function in which aa or bb genotypes are
high risk, but not in the presence of the nonhomologous
homozygote. Figure 1B shows an example Petri net model
that is consistent with the pattern of high-risk and low-
risk cells in the XOR-based penetrance function. The
importance of this result is that it shows how a simple
discrete biochemical systems model can account for the
nonlinear pattern observed in the XOR model. Although
not an actual biological result, this thought experiment
shows that a simple system can generate a complex genetic
architecture that is not predicted by a one-SNP-at-a-time
analytical approach. As reviewed by Moore and Williams,
this represents a ﬁrst step toward making the connection
between biological and statistical epistasis.29 Indeed,
others have demonstrated biologically plausible models
for transcriptional and biochemical networks that are
consistent with the nonlinear XOR function.35,36
It is important to note that the data supporting epistasis
in complex human diseases are emerging slowly. This is
not surprising given that decisions to use models that do
not incorporate complex interactions are based primarily
on hypotheses of convenience and not on plausible
biological phenomena that are inherently complex. There-
fore, it is important to carefully consider biological plausi-
bility in addition to analytical simplicity in designing anal-
yses. The roles for experimental genetics and systems
biology in constructing well-founded hypotheses of
disease etiology are discussed below with this in mind.
Why Is Epistasis so Ubiquitous?
Moore37 and Templeton,24 for example, have argued that
epistasis is likely to be a ubiquitous component of the
genetic architecture of common human diseases. There
are several reasons for this. First, as noted above, epistasisJournal of Human Genetics 85, 309–320, September 11, 2009 311
is not a new idea and remains a common phenomenon in
the biological literature. Second, the ubiquity of biomolec-
ular interactions in gene regulation and biochemical and
metabolic systems suggests that the relationship between
DNA sequence variations and biological endpoints is
likely to involve interactions of multiple gene products.
Third, positive results from studies of single polymor-
phisms typically do not replicate across independent
samples. Fourth, and perhaps most importantly, epistasis
is commonly found when properly investigated. These
four reasons suggest that epistasis may be ubiquitous in
human biology but do not provide an explanation for
why. For that, we turn to evolutionary biology for a theory
that may provide a compelling mechanism for epistasis.
Canalization is an idea introduced by Waddington to
explain the buffering of phenotypes to genetic and envi-
ronmental perturbations.38 Evolutionary biologists have
described canalization as stabilizing selection that ensures
that systems evolve to a robust level.39 In other words,
evolution seeks to keep our blood pressure, glucose levels,
and other important physiological and metabolic systems
in a healthy range while ensuring that these measures are
resistant to most genetic and environmental perturba-
tions. Deviations from these healthy ranges are often cate-
gorized as diseases such as hypertension and diabetes. One
manner in which evolution has succeeded in developing
robust systems is by evolving redundant gene networks
that are resistant to ﬂuctuations, both genetic and environ-
mental. This might explain why epistasis is so ubiquitous
within the context of human disease. What we observe
as disease might be the result of the accumulation of
multiple mutations in different parts of a gene network
that are needed to perturb a robust system from its evolved
range. This might explain why most single variants
explain very little of the risk for any given common
disease. If this is true, it is essential to look for combina-
tions of genetic variations in human populations as
a way to capture the patterns of variation across networks
that are needed to move individuals into unhealthy or
disease phenotypes such as hypertension. In essence,
evolution moves a population to a state where the vast
majority of people are healthy, and this is often accom-
plished through complex networks that involve substan-
tial epistasis. Epistasis as a robust gene network phenom-
enon has recently been discussed by Tyler et al.16
Assuming canalization has shaped human biology
throughout history, one might ask why we see indepen-
dent main effects in genetic association studies at all.
Gibson suggests that human migration and recent bottle-
necks might allow hidden or cryptic genetic variation to
emerge as genetic risk factors.39 Our recent evolutionary
history may explain why genetic architecture is likely
to be a mix of different types of genetic effects includ-
ing epistasis, gene-environment interactions, and locus
heterogeneity. Unfortunately, canalization is very difﬁcult
to determine experimentally. Nevertheless, it provides an
important foundation to begin thinking about why the312 The American Journal of Human Genetics 85, 309–320, Septemgenetic architecture of common diseases is so complex.
Gibson offers a few strategies for identifying the hallmarks
of canalization.39
The Challenges of Detecting Statistical Epistasis
in Genetic Association Studies
As discussed above, one of the early deﬁnitions of epistasis
was deviation from additivity in a linear model.30 The
linear model plays an important role in modern genetic
epidemiology because it has a solid theoretical foundation,
is easy to implement with a wide range of different
software packages, and is easy to interpret. Despite these
good reasons to use linear models,27,28 they do have limi-
tations for explaining genetic models of disease because
they have limited ability to detect nonlinear patterns of
interaction.40 The ﬁrst problem is that modeling interac-
tions requires looking at combinations of variables.
Considering multiple variables simultaneously is chal-
lenging because the available data get spread thinly across
multiple combinations of genotypes. Estimation of param-
eters in a linear model can be very problematic when the
data are sparse. The second problem is that linear models
are often implemented such that interaction effects are
only considered after signiﬁcant independent main effects
are identiﬁed. This certainlymakesmodel ﬁtting easier, but
it assumes that the most important predictors will have
main effects. For example, the focused interaction testing
framework (FITF) approach of Millstein et al. provides
a powerful logistic regression approach to detecting inter-
actions but conditions on main effects.41 Furthermore, it
is well documented that linear models have greater power
to detect main effects than interactions.42–44 Therefore, in
using linear models, we are constrained not by biological
reality but by statistical tools that were not necessarily
developed to test realistic biological models. As a ﬁeld,
genetic epidemiology has preferred Fisher’s deﬁnition of
epistasis to Bateson’s, and this has led to analytical
approaches that signiﬁcantly hurt our ability to model
real genetic architecture. In fact, the historical sidetracking
of Bateson’s biological epistasis for Fisher’s statistical deﬁ-
nition, which he called ‘‘epistacy,’’ has been noted.20 The
limitations of the linear model and other parametric statis-
tical approaches have motivated the development of
computational approaches such as those from machine
learning and data mining that make fewer assumptions
about the functional form of the model and the effects
being modeled.45–47 Several recent reviews highlight the
need for newmethods48 and discuss and compare different
strategies for detecting statistical epistasis.28,49 The
methods reviewed by Cordell28 include novel approaches
such as combinatorial partitioning50,51 and logic regres-
sion52,53 and machine learning approaches such as
random forests,54,55 for example. We brieﬂy review one
of these novel methods, multifactor dimensionality reduc-
tion (MDR), in the next section.
In addition to the challenge of modeling nonlinear
interactions, GWAS introduces important computationalber 11, 2009
challenges. The detection of epistasis in the absence of
signiﬁcant main effects requires combinations of SNPs to
be systematically evaluated. As summarized by Moore
and Ritchie56 and Moore,57 combinatorial assessment of
SNPs in a GWAS is not computationally feasible beyond
exploring two-way and three-way combinations. As we
will brieﬂy describe in the next section, addressing this
problem will require using prior statistical and biological
knowledge, because there are not enough computers in
the world for a brute-force approach.
Finally, perhaps themost important challenge we face in
detecting and characterizing epistasis is interpretation. As
discussed above, going from a population-level statistical
summary of gene-gene interactions to inferences about
the biological interactions occurring at the cellular level
is a signiﬁcant and difﬁcult leap. Conversely, translating
our knowledge of gene networks and cellular function at
the individual level to predictions about public health is
equally difﬁcult. As discussed by Moore and Williams,
systems biology holds the promise to help us traverse
this conceptual and practical divide.29
A Multifactor Dimensionality Reduction Approach
to Modeling Statistical Epistasis
Thornton-Wells et al. have suggested that we need an
analytical retooling to address the etiological complexity
of common human disease.48 As such, several novel
approaches have been developed that are designed specif-
ically to tackle complex problems such as modeling epis-
tasis. As reviewed recently by Cordell,28 multifactor dimen-
sionality reduction (MDR) has emerged as one important
new method for detecting and characterizing patterns of
statistical epistasis in genetic association studies that
complements the linear modeling paradigm. MDR was
developed as a nonparametric (i.e., no parameters are esti-
mated) and genetic model-free (i.e., no genetic model is
assumed) data mining and machine learning strategy for
identifying combinations of discrete genetic and environ-
mental factors that are predictive of a discrete clinical
endpoint.57–63 Unlike most other methods, MDR was
designed to detect interactions in the absence of detectable
main effects and thus complements statistical approaches,
such as logistic regression, andmachine learning methods,
such as random forests and neural networks. At the heart
of the MDR approach is a feature or attribute construction
algorithm that creates a new variable or attribute by pool-
ing genotypes from multiple SNPs. The general process of
deﬁning a new attribute as a function of two or more other
attributes is referred to as constructive induction, or attri-
bute construction, and was ﬁrst described by Michalski.64
Constructive induction, using the MDR kernel, is accom-
plished in the following manner. Given a threshold T,
a multilocus genotype combination is considered high
risk if the ratio of cases (subjects with disease) to controls
(healthy subjects) exceeds T; otherwise, it is considered
low risk. Genotype combinations considered to be high
risk are labeled G1, whereas those considered low risk areThe Americanlabeled G0. This process constructs a new one-dimensional
attribute with values of G0 and G1. It is this new single
variable that is assessed, via any classiﬁcation method.
The MDR method is based on the idea that changing the
representation space of the data will make it easier for
methods such as logistic regression, classiﬁcation trees, or
a naive Bayes classiﬁer to detect attribute dependencies.
As such, MDR signiﬁcantly complements other classiﬁca-
tion methods such as those reviewed by Hastie et al.46
This method has been conﬁrmed in numerous simulation
studies, and a user-friendly open-source MDR software
package written in Java is freely available.
Since its initial description by Ritchie et al.,58 many
modiﬁcations and extensions toMDR have been proposed.
These include, for example, entropy-based interpretation
methods,63 the use of odds ratios,65 log-linear methods,66
generalized linear models,67 methods for imbalanced
data,68 permutation testing methods,69 methods for
missing data,70 and different evaluation metrics.71–73 The
MDR approach has also been successfully applied to
a wide range of different genetic association studies. For
example, Andrew et al.74 used MDR to model the relation-
ship between polymorphisms in DNA repair enzyme genes
and susceptibility to bladder cancer (MIM 109800). A
highly signiﬁcant nonadditive interaction was found
between two SNPs in the xeroderma pigmentosum group
D (XPD) gene (MIM 278730) that was a better predictor
of bladder cancer than smoking. These results were later
replicated in independent studies from a consortium.75
As discussed above, the biggest challenge to implement-
ing methods such as MDR in GWAS is the combinatorial
explosion of SNP interactions. The focus of many current
MDR studies is on scaling this approach to GWAS data.
Other than faster computer hardware for MDR76 or parallel
implementations,77 there are two general strategies that
are being pursued,57,78 each of which has advantages and
disadvantages.79 The ﬁrst is a ﬁlter approach that preselects
SNPs that are likely to interact prior to MDR analysis63,80.
Machine learning methods based on the ReliefF algo-
rithm81 look promising as statistical ﬁlter approaches for
GWAS.82–84 The second approach is the use of stochastic
search algorithms, such as those reviewed by Michalewicz
and Fogel,85 to guide an MDR analysis. Methods based
on evolutionary computing algorithms that perform
parallel stochastic searches across MDR models have been
extensively explored.57,78,86–91 The key to the success of
these algorithms is the availability of either statistical
or biological knowledge that can be used to prioritize
certain SNPs in the search process.78,91 Otherwise, the
algorithm is searching for a genetic needle in an effectively
inﬁnite genomic haystack. For example, Moore and
White86,87 showed how preprocessed ReliefF scores can
be used to provide good building blocks for an evolu-
tionary computing algorithm, and Pattin et al.92 reviewed
a role for protein-protein interaction databases as a source
of biological knowledge that could be used in the same
manner.Journal of Human Genetics 85, 309–320, September 11, 2009 313
Implications of Epistasis for Personal Genetics
The current personal genetics paradigm that is being
marketed directly to the consumer is built on the results
of genetic association studies that ignore the complexity
of the genotype-to-phenotype mapping relationship that
results from epistasis and other phenomena. Indeed, it is
now apparent that single SNPs typically have very small
effects on risk and are not useful for predicting risk.11,12
This presents a signiﬁcant problem for those hoping to
capitalize on SNPs or other genetic variations as useful
markers of health and disease. We propose here that the
full utility of personal genetics will not be realized until
the full complexity of genetic architecture is embraced
rather than ignored. For this to become a reality, those con-
ducting genetic association studies will need to rigorously
test hypotheses about epistasis, gene-environment interac-
tion, locus heterogeneity, etc. via analytical methods that
are powered to detect these phenomena. These results
need to be reported for every study, in addition to the stan-
dard analyses reporting independent SNP effects. This will
of course not be easy for some of the reasons outlined
above, but it is absolutely necessary if we expect to bring
genetics to the consumer in a meaningful manner.
To illustrate this point, all one needs to do is consider
a well-characterized family history, which remains the
most powerful predictor we have about risk for common
diseases. As Kardia et al. discuss, a carefully recorded family
history of coronary heart disease (CHD) is a powerful indi-
cator of future risk even after adjustment for the effects of
traditional risk factors such as age, smoking, and body
mass index.93 Family history captures large amounts of
genomic and environmental sharing among relatives,
and it implicitly incorporates nonlinear aspects. Therefore,
family history provides genome-wide and not gene-
speciﬁc risk, thereby enabling a better model of risk. Given
these facts, genetic data analyses using a linear model will
never approach the simplicity and cost effectiveness of
using family history to identify individuals at risk for
CHD. This is particularly true if we assume that epistasis
and gene-environment interactions play an important
role in disease susceptibility, as is expected for CHD94
and its risk factors.95
Consider type 2 diabetes, or T2D (MIM 125853), as an
example. As with CHD, family history of T2D is a strong
predictor of risk. However, as noted by Williams et al., the
results of GWAS analysis of T2D have been mixed, and it
does not appear that the known genetic risk factors yet
approach the predictive power of family history.96 To illus-
trate this point, the authors present in Figure 2 their
consumer genetic testing results for T2D from one of the
available services, 23andMe. Note that none of the poly-
morphisms reported have genotypes with maximum
relative risk levels above 2. In fact, as noted earlier, most
have amaximum relative risk level of less than 1.5. Overall,
this combination results in very small increases or decreases
in risk, as is seen for the results for each author. The progres-
sion from single SNPs as risk factors to combinations of314 The American Journal of Human Genetics 85, 309–320, SeptemSNPs acting epistatically to the entire genomeas a risk factor
was recently discussed by Moore, who proposed that our
individual ‘‘genometype’’ may ultimately prove the most
useful strategy for personal genetics.97 This is consistent
for the power of family history and, if true, suggests that
we need to fundamentally change our approach to genetic
associationanalysis if the results are tobeuseful forpersonal
genetics and other endeavors in human genetics.
Recommendations for Personal Genetics
We have presented here an introduction to epistasis,
a theory for why epistasis is so common in human biology,
a summary of the challenges in detecting and character-
izing epistasis in genetic association studies, a summary
of theMDRmethod for modeling epistasis, and a summary
of the implications of epistasis for personal genetics.
Below, we present ﬁve recommendations for what we can
do to improve the usefulness of genetic association results
for the providers and the consumers of personal genetics.
We believe this should be a research priority given the
central motivation in human genetics to deliver new
knowledge that improves human health. Personal genetics
may play an important role in the delivery of healthcare
beneﬁts by initially fostering a patient-physician dialog
about results and perhaps even later by providing person-
alized genetics that will tailor treatment and prevention
strategies to individual patients.
First, we need to greatly improve our knowledge of bio-
logical and statistical epistasis and its role in human health
and disease. We know very little about the role of epistasis
in human biology and public health because the focus for
so long has been on the effects of single genes and single
genetic variants in biological and clinical endpoints. Given
Figure 2. Panel of Genetic Markers for Type 2 Diabetes
Provided by 23andMe for Each of the Authors
The proﬁle of author A (gray bars) is associated with an overall
slight decrease in risk under a multiplicative model, whereas the
proﬁle of author B (black bars) is associated with a slightly
increased risk. Note that all adjusted odds ratios for individual
genotypes are between 0.8 and 1.2.ber 11, 2009
the ubiquity of complexity in genetic architecture, with
epistasis as a central component, we need to rephrase our
research questions with this in mind. Instead of asking
which SNP is associated with disease, we should be asking
which combination of SNPs is associated with disease.
Rephrasing the question in this manner necessitates
a redeﬁnition of the null hypotheses that needs to be
tested via statistical and computational methods. The
current status quo is to test the universal null hypothesis
of no association via only linear statistical methods.
Rejection of this null hypothesis allows an investigator to
draw inferences about independent genetic effects but
not nonlinear epistatic effects. Given that complexity,
including epistasis, is likely a substantial component of
biological reality, we propose the following set of plausible
hypotheses for retooling our analytical approach to this
problem. First, we recommend as a starting point to test
the null hypothesis that the associations in the data are
only linear and additive. A null hypothesis of linearity is
consistent with the hypothesis testing in the status quo.
For example, one could test the linear null hypothesis via
methods such as MDR that were designed to model
nonlinear interactions. Once the linear null hypothesis
has been tested via proper nonlinear methods, the logical
next step is to test the universal null hypothesis of no
association via linear statistical methods that model the
independent and additive effects. Rejection of the uni-
versal null, in addition to the linear null, provides a set
of results generated in a systematic manner that embraces
complexity. These results can then be interpreted biologi-
cally via experimental methods or can be interpreted statis-
tically via approaches such as parsimony or information
theory. At present, this proposal is more of a philosophical
exercise than a practical one because fast and powerful
analytical tools and software for detecting epistasis on
a genome-wide scale are not yet available. Additionally, it
is important to design these analyses to compensate for
multiple testing issues that exist as part of evaluating
interactions. Despite some of these current practical limita-
tions, the biological evidence for epistasis is compelling
enough to suggest that there are very few loci in the
genome that will have universal effects on disease risk on
the order of that seen, for example, for the apolipoprotein
E (APOE) gene (MIM 107741) and Alzheimer’s disease
(MIM 104300). As such, we need to design our analyses
accordingly. Genetic epidemiology has shaken the trees
and picked the low-hanging fruit. It is time to climb the
branches to identify the hard-to-reach fruit and to search
for low-hanging fruit from a different perspective (see
Figure 3).
With the above in mind, it is important to note that the
current one-SNP-at-a-time approach to GWAS analysis that
puts so much weight on replication98 can actually provide
important clues about the complexity of the underlying
genetic architecture. For example, a recent study by Greene
et al. demonstrated that failure to replicate a genetic asso-
ciation in a second independent sample can be an indica-The Americantion that single SNPs contribute to disease susceptibility
through nonlinear interactions with one or more other
SNPs.99 Greene et al. showed that the power to replicate
a SNP with a signiﬁcant main effect can drop from more
than 80% to less than 20% with a change in allele
frequency at a second interacting SNP of less than 0.1.99
Such small changes in allele frequency are often observed
even when the replication sample is taken from the same
population. This study recommended that SNPs that fail
to replicate be followed up with epistasis analysis to check
for interaction. This of course introduces epistasis analysis
as an afterthought to a main-effects analysis, an approach
that we now argue is inadequate. This study also raises the
question of how much weight we should put on statistical
replication under the assumption of complexity.
The believability of a statistical result relies more on the
biological interpretation and experimental evidence than
it does on the actual statistical ﬁnding.99 Indeed, Bush
et al.,100Holmanset al.,101 andSacconeet al.102have shown
that using biological knowledge to guide genetic associa-
tion studies may provide more meaningful results. Yu
et al. provide a hypothesis-testing framework for
combining multiple SNPs from the same gene or from
multiple genes in a pathway-based manner.103 Askland
et al. recently showed that patterns of SNPs in biological
pathways are more likely to replicate than individual SNPs





Figure 3. Low-Hanging and High-Hanging Genetic Fruit
Under the assumption that common diseases have a complex
genetic architecture, we expect there to be few SNPs with
moderate to large independent and additive main effects on
disease susceptibility (i.e., low-hanging fruit). Rather, most SNPs
of interest will be nestled in the branches and will only be found
by embracing the complexity of the genotype-to-phenotype
mapping relationship that is likely to be characterized by
nonlinear gene-gene interactions and other phenomena such as
gene-environment interaction and locus heterogeneity.Journal of Human Genetics 85, 309–320, September 11, 2009 315
not even begin to analyze a GWAS study until we have
exhaustively studied each candidate gene and each
pathway; only then will we have the appropriate knowl-
edge base to make sense of GWAS results.105 As Moore
noted, there is a major shift in the ﬁeld of genetic epidemi-
ology away from the purely statistical approaches to more
bioinformatic approaches that consider knowledge about
gene function, gene networks, and biochemical path-
ways.97 2009 perhaps marks the turning point toward
more of a systems approach that recognizes the role of
epistasis and other complexities in genetic architecture.
Second, we need powerful analytical tools that are
designed to address the complexity of genetic architecture
resulting from epistasis and other phenomena. There is
an important role for biostatisticians, bioinformaticists,
and other analytically trained scientists in developing the
next generation of statistical and computational tools
that will embrace and directly confront the complexity
that confounds current genetic association studies. The
MDR algorithm that we brieﬂy summarized here is a start,
but it is only one example of the types of tools needed.
Such tools are likely to come from the machine learning
and data mining communities that are actively engaged
in solving complex problems in other disciplines such as
economics and engineering. In addition to powerful algo-
rithms, we also need user-friendly software that can be
used by geneticists and epidemiologists. As reviewed by
Moore, these software packages need to be designed so
that they are easy enough for a biologist to use but power-
ful and ﬂexible enough for a statistician or computer scien-
tist to use.106 Moore suggests that the ideal analysis will be
performed by the geneticist and the bioinformaticist
jointly so that they can communicate information about
the problem and the algorithms in real time.106
Third, we need better experimentalmethods for conﬁrm-
ing statistical models of epistasis in animal models or in
human cell culture. Interpreting genetic associations for
common diseases such as type 1107,108 and type 2109,110
diabetes has not been easy, and it is clear that making
inferences about etiology from any genetic model is a
signiﬁcant ongoing challenge.111 Ultimately, we will need
to rely on experimental biology to validate our genetic
models. Although we are very good at perturbing single
genes or pairs of genes, we are not very good at designing
experiments to perturb complex systems. A call for
multifactorial perturbation experiments has been made,
but there has been little progress toward this end.112 A
step in the right direction is the Collaborative Cross initia-
tive from the Complex Trait Consortium, which aims to
develop a common reference panel of recombinant inbred
mice that each have a mixture of genomes from several
laboratory strains of mice and several wild strains.113,114
This resource will provide a panel of mice for experimenta-
tion that more closely resembles the natural distribution of
genetic diversity in humans than the widely used inbred
laboratory strains do. Similar resources in other model
systems such as Drosophila are also being developed.115316 The American Journal of Human Genetics 85, 309–320, SeptemOur ability to make full use of these panels and other
resources to study epistasis will depend critically on our
ability to perturb multiple genes simultaneously in these
systems in a high-throughput manner.
Fourth, we need to remember the principles of classical
genetics as we immerse ourselves in the excitement of
cutting-edge genotyping technology that makes GWAS
possible as well as in the emerging methods to rapidly
sequence the entire genome. Indeed, Miller and Hol-
lander116 cautioned geneticists 15 years ago to not divert
our attention elsewhere in light of ‘‘wondrous new molec-
ular techniques.’’ This warning has been largely ignored.
For example, pedigrees have been put aside in favor of large
population-based case-control studies for GWAS. We
predict there will be a return to pedigree-based studies
and other methods consistent with classical genetics as it
is realized that technology-centric approaches have signif-
icant shortcomings. The idea that pedigrees are still useful
is supported by Culverhouse et al., who showed that purely
epistatic models can give rise to increased allele sharing
between affected siblings even in the absence of variation
resulting from additivity or dominance.31 Of course, as
mentioned above, we still need to develop the analytical
tools to model epistasis in pedigree-based studies. The inte-
gration of the pedigree disequilibrium test (PDT) of Martin
et al.117,118 with the MDR method described above has
yielded a novel MDR-PDT approach to detecting interac-
tions in general pedigrees.119 This is of course only a start,
but it is a step in the right direction. The only way to
ensure that classical genetics is not forgotten in the geno-
mics age is to make an effort to teach the classical concepts
from the original literature in graduate school. This is often
passed over in favor of recent literature onGWAS and other
genomics methodologies. It is the blend of classical
genetics with modern genetics that gives us the maximum
ability to reveal the details of genetic architecture that are
necessary for personal genetics.
Finally, we need to continue to integrate systems biology
into human genetics in a meaningful manner. As Moore
and Williams have discussed, one of the greatest contribu-
tions to our understanding of biological organisms was the
merger of Darwin’s evolution of species by natural selec-
tion and Mendel’s principles of heredity.29 This merger
was referred to as ‘‘the modern synthesis’’ by Huxley120
and others, and it paved the way for evolutionary and
population genetics as we know them today. We are pres-
ently undergoing a ‘‘more modern’’ synthesis that merges
multiple disciplines into what has been referred to as
systems biology.121 One goal of systems biology is to efﬁ-
ciently, accurately, and inexpensively measure most if
not all of the biomolecules involved in one or more
biochemical or physiological systems. Only after all of
the relevant information is available will it be possible to
mathematically model biomolecules with respect to inter-
individual phenotypic differences. We argue that the vast
divide between biological and statistical epistasis will
only be narrowed by our success in applying systemsber 11, 2009
biology to genetics problems.122 Our ability to measure
information at multiple levels in the hierarchy between
genes and disease will provide the basis for interpreting
statistical models. Of course, more data is not the same as
more knowledge, and our ability to translate systems
biology into a deeper understanding of epistasis and
human disease will depend critically on our analytical
framework and the simplifying assumptions that we make.
Recognition of the complexity of genetic architecture
and successful progress in terms of these ﬁve recommenda-
tions will provide the knowledge base that will be neces-
sary for personal genetics to have the kind of impact on
human health that we would all like to see. It is interesting
to note that the focus on complexity in human genetics
is not a new idea. More than 50 years ago, Snyder123 sug-
gested that ‘‘if human genetics is to progress along fresh
pathways, the traditional atomistic approach must be
supplemented by new methods which will provide infor-
mation on multifactorial inheritance’’ and that ‘‘We must
be able to analyze genetic variability without recourse to
classical single-gene analyses.’’ It is time for the human
genetics community to embrace the complexity of human
traits that was recognized by Snyder and others before
many current human geneticists were born.
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